Evidence map›Paper›PMID 23990666›Full record

ArticleJournal of the National Cancer Institute2013

Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.

Michelle C Desimone, W Kimryn Rathmell, David W Threadgill

Open access · hybridAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Kidney Cancer Risk Associated with Historic Groundwater Trichloroethylene Contamination.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. PRODIGY: personalized prioritization of driver genes.Bioinformatics (Oxford, England) · 2020
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michelle C DesimoneAffiliations of authors: Department of Genetics, North Carolina State University, Raleigh, NC (MCD, DWT); Department of Genetics (WKR) and Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC (WKR, DWT).
W Kimryn Rathmell
David W Threadgill
North Carolina State University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC CLINICAL AND TRANSLATIONAL SCIENCE AWARD: BPCAUL1RR025747 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2008 to 2011
$44.6M
UNC Clinical and Translational Science AwardUL1TR000083 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2012 to 2013
$11.6M
Modeling heterogeneity for safe cancer prevention and detectionU01CA105417 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THREADGILL, DAVID W. · 2004 to 2013
$6.7M
Genetic Events in the Development of Renal Cell CarcinomaR01CA121781 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RATHMELL, WENDY KIMRYN · 2007 to 2011
$1.4M
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR000083NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA105417NCI NIH HHS R01 CA121781NCRR NIH HHS UL1 RR025747
6 · The paper itself

Abstract

backgroundThe risk relevance of the P81S von Hippel-Lindau (VHL) gene hotspot mutation identified in clear cell renal cell carcinoma from individuals exposed occupationally to trichloroethylene (TCE) is not known. VHL mutations in hereditary VHL syndrome strongly correlate with phenotypic associations, but specific sporadic mutations in VHL that uniquely alter its protein function may provide a selective growth advantage for somatic cells harboring these mutations.

methodsVHL deficient (Vhl (-/-) ) mouse embryonic stem cells were generated that stably express wild-type, P81S, or R167Q human VHL protein. Under hypoxic conditions, cell lines were examined for hypoxia-inducible transcription factor family (HIF) stabilization and E3-ubiquitin ligase complex interactions. In vivo, teratomas were examined for tumor size, proliferation, apoptosis, and immunohistochemistry and subjected to gene expression analysis. Wild-type, R167Q, and P81S VHL-expressing teratomas were also exposed to 5 Gy ionizing radiation to quantify apoptotic response. Proliferation and apoptosis and teratoma growth were analyzed by either Student t test or analysis of variance with Bonferroni correction. All statistical tests were two-sided.

resultsThe P81S VHL mutation produces deregulation of HIF factors in cell culture but exhibits a growth advantage in the tumor microenvironment, in part because of suppression of apoptosis (P81S mean = 0.9%, 95% confidence interval = 0.6 to 1.2%; WT mean = 7.6%; 95% confidence interval = 6.4 to 8.8%; P < .001) coupled with sustained proliferation. Transcriptional analysis of P81S teratomas revealed the induction of metabolic pathways, antiapoptotic genes, and global suppression of key DNA damage response genes not observed in VHL wild-type or R167Q mutants. In vivo irradiation exposure showed that P81S mutant is resistant to ionizing radiation-induced apoptosis.

conclusionsThe TCE-associated P81S VHL mutation can initiate a unique adaptive response required for selective tumor growth through pleiotropic effects on metabolic diversification, apoptosis suppression, and alteration of the DNA damage response.

Indexed as

DNA DamagePoint MutationAnimalsApoptosisArginineAtaxia Telangiectasia Mutated ProteinsCarcinoma, Renal CellCell Cycle ProteinsDNA-Binding ProteinsEmbryonic Stem CellsGlutamineHumansHypoxia-Inducible Factor 1ImmunohistochemistryKidney NeoplasmsMiceArginineAtaxia Telangiectasia Mutated ProteinsATM protein, humanAtm protein, mouseCell Cycle ProteinsDNA-Binding ProteinsGlutamineHypoxia-Inducible Factor 1ProlineProtein Serine-Threonine KinasesSerineTrichloroethyleneTumor Suppressor ProteinsUbiquitin-Protein LigasesVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID23990666
PMCPMC3776265
OpenAlexW2140563244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.